Luncheon Symposium: Update on the Efficacy and Safety of Dutasteride in the Management of Androgenetic Alopecia

This review highlights the use of finasteride, a 5alpha-reductase inhibitor, for treating benign prostatic hyperplasia and male pattern hair loss, noting that it may cause male sexual dysfunction but usually with tolerable side effects that decrease over time, not requiring treatment discontinuation.

This study found that finasteride caused adverse effects on liver, kidney, and heart tissues in female mice, raising concerns about its potential use in females for treating androgenetic alopecia.

This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.

This abstract indicates that finasteride, at a dose of 1 mg per day, is effective in treating androgenetic alopecia in men by significantly reducing DHT levels.

Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

Dutasteride reduces DHT more effectively than finasteride.

This review discusses advances in 5α-reductase inhibitors for treating male androgenetic alopecia and reports no new clinical results.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.

In this study, the combination of finasteride and minoxidil significantly increased hair growth in balding male stumptail macaques compared to each drug alone.